TVTX Q4 2022 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M-2.4% YoY

Gross Profit

$54M96.9% margin

Operating Income

-$67M-119.7% margin

Net Income

-$66M-117.8% margin

EPS (Diluted)

$-1.03

QoQ Revenue Growth

+4.4%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$55M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$673M

Total Liabilities

$630M

Stockholders' Equity

$43M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$57M	-2.4%
Gross Profit	$54M	$55M	-2.2%
Operating Income	-$67M	-$47M	-41.7%
Net Income	-$66M	-$52M	-27.6%

Revenue Segments

Product

$52M50%

Bile Acid Products

$27M25%

Tiopronin Products

$26M25%